Aim: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. Methods: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. Results: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and lp/19q co-deletion (p = 0.035) correlated with overall survival. Conclusion: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? / Franceschi, E., Mura, A., De Biase, D., Tallini, G., Pession, A., Foschini, M.P., Danieli, D., Pizzolitto, S., Zunarelli, E., Lanza, G., Bartolini, D., Silini, E.M., Visani, M., Di Oto, E., Tosoni, A., Minichillo, S., Lamberti, G., Lanese, A., Paccapelo, A., Bartolini, S., et al.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 14:16(2018), pp. 1559-1567. [10.2217/fon-2017-0634]
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival?
Silini E. M.;
2018-01-01
Abstract
Aim: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. Methods: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. Results: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and lp/19q co-deletion (p = 0.035) correlated with overall survival. Conclusion: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
